I am honored to receive this grant for sirolimus trial in RUNX1-FPD @ACSNews@RUNX1Research & thanks to collaborators Dr. DiNardo @UTMDAnderson@CLachowiez Dr.Lucero, @KellyLBolton Drs. Cantor & Frelinger, patients/families to support our mission of early intervention/prevention
A new award will enable researchers at @OHSUNews to test an anti-inflammatory drug for patients at heightened risk of developing leukemia due to an inherited mutation in the RUNX1 gene.
@LabAgarwal will serve as the principal investigator at OHSU: https://t.co/7vTmXArTEt
At @theNCI, our mission is simple: reduce the burden of cancer.
That means moving faster—from discovery to patient impact—and doing it together.
Follow along as we work to drive the next generation of breakthroughs.
I am honored to receive this grant @OHSUKnight for sirolimus trial in RUNX1-FPD & thankful to @RUNX1Research@ACSNews collaborators Dr. DiNardo @CLachowiez Dr.Lucero, @KellyLBolton Drs. Cantor & Frelinger, patients/families to support our mission of early intervention/prevention
We’re proud to co-fund a new $1.89M LEAP Grant with @AmericanCancer to support an expanded clinical trial at @OHSUKnight and @LabAgarwal.
The study is evaluating a low dose of sirolimus in individuals with RUNX1-FPD to determine safe dosing, an important step in ongoing research toward #bloodcancer prevention and intervention for this high-risk community.
Read more: https://t.co/J9ZyIeP8Xk
📣 Save the Date | Oregon Drug Discovery Symposium (ODDS) 2026
The symposium takes place April 8–9, 2026, and will feature scientific talks, discussions, and a poster session, providing a forum for knowledge exchange across disciplines.
Register: https://t.co/naUMxRkXQ3
Join us for Knight School to learn about the latest advances in cancer early detection, including clinical trials and early detection blood tests.
📍 Knight Cancer Research Building
⌚️ 5:30 pm
🗓️ March 31
🎟️ FREE
https://t.co/lRwHvodh3L
@OHSUKnight Thank you Pediatric Cancer Research Foundation for supporting @LabAgarwal@OHSUKnight, we are thrilled to receive this award for this highly impactful work focused on understanding role of inflammation in young individuals with rare leukemia predisposition syndrome.
The National Cancer Advisory Board meets March 16–17. NCAB helps shape NCI’s research priorities and funding decisions, guiding the direction of our nation’s cancer efforts. I encourage you to join the open session via videocast and stay engaged.
https://t.co/CPQjauMdyU
#NCAB
Merry Christmas🎄& Happy Holidays to all from @LabAgarwal@OHSUKnight. Despite of challenging year we had lots of exciting things- new publications, grants, & celebrations. Thanks to our resilient team & support from friends, family & science community, looking forward to 2026💕